Cambridge-based Morphogen-IX just raised a £1.5 seed round led by Index Ventures. The company is a spin-out from Cambridge University which is working on a treatment for pulmonary arterial hypertension (PAH) which affects about 6,500 people in the UK alone. PAH is caused by the narrowing of blood vessels that lead from the heart to the lungs. When these arteries narrow, it becomes harder for the heart to pump blood through to the lungs, leading to breathlessness and heart failure.
The round also included investment from Cambridge Innovation Capital and Cambridge Enterprise Seed Funds. The company says it’s dedicated to developing a therapy that will focus on the disease versus just treating the symptoms.
Welcome to the JAG Shaw Baker blog. This is the place where we talk about clients, current news affecting the start-up community, trends in life sciences, digital technology and clean tech markets and even some opinions on legal matters affecting high-growth companies today. We welcome your comments!
If you would like any information on JAG Shaw Baker, please email our marketing department: firstname.lastname@example.org
Jennifer Kite-Powell, Content Editor
Kendell McGifford, Marketing Executive
Previous PostCrossing The Valley Of Death: Funding, Financing And Strategy At Biotech & Money London
Next PostTina Baker Talks About How To Tackle Early-Stage Legals In Seedcamp Podcast
London / JAG Shaw Baker / Berners House / 47-48 Berners Street / London / W1T 3NF
Edinburgh / JAG Shaw Baker / 14-18 Hill Street / Edinburgh / EH2 3JZ
Cambridge / JAG Shaw Baker / Leda House / 20 Station Road / Cambridge / CB1 2JD
A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. more information
A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree.
We use the following cookies:
• Strictly necessary cookies. These are cookies that are required for the operation of our website. They include, for example, cookies that enable you to return to a previous page.
• Analytical/performance cookies. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. The analytical/performance cookies are provided on our behalf by Google Inc. to aid with reporting of user behaviour, market research and improving website functionality. This user behaviour is analysed in order to improve this website. To see how this applies to Google Analytics, visit http://www.google.co.uk/intl/en/analytics/privacyoverview.html. You can stop tracking by Google Analytics by visiting https://tools.google.com/dlpage/gaoptout?hl=en-GB.
The strictly necessary session cookies are a temporary cookie which remains in the cookie file of your browser until you close the browser. The other cookies will remain in the cookie file of your browser after the closing of the browser, and will become active again when you reopen this website. The different cookies have different expiration dates. Following expiry of a cookie, a new version of that cookie will be downloaded when you next visit this website, unless you have withdrawn your consent in the meantime.
You can block cookies by activating the setting on your browser that allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or parts of our website.